Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Announces Class Action Lawsuit on Behalf...

Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Announces Class Action Lawsuit on Behalf of Investors of CellCyte Genetics Corporation

WASHINGTON--(Business Wire)--
The law firm of Cohen, Milstein, Hausfeld & Toll, P.L.L.C.
announced today that it has filed a class action complaint in the
United States District Court for the Western District of Washington on
behalf of purchasers of CellCyte Genetics Corporation common stock
("CellCyte" or "the Company") (OTC: CCYG) from April 6, 2007 through
January 9, 2008, inclusive (the "Class Period").

The complaint charges CellCyte, certain of its officers and
directors, and two others who were primary participants in the sale of
the Company's stock with violations of the Securities Exchange Act of
1934. During the Class Period, CellCyte held itself out to be "a
company focused on the discovery and development of stem cell enabling
therapeutic products." The complaint alleges that CellCyte executives
and business partners misled investors during the Class Period by
publishing false information about the history and experience of the
company's chief executive officer Gary A. Reys. Reys' background was
called into question after published news reports called out alleged
discrepancies relating to Reys' finance degree from the University of
Washington, a CPA designation, ties to the Washington Society of
Certified Public Accountants, and a strong track record within the
pharmaceutical industry.

According to the complaint, CellCyte made misleading and false
statements about Reys to potential investors and the SEC. These
published statements had the cause and effect of creating an
unrealistically positive assessment of CellCyte's prospects for
investors. As a result, stock prices for the company were artificially
inflated during the Class Period. Soon after Reys' credibility came
into question the suit claims CellCyte took some of Reys' biographical
information off its Web site. Within days of the removal company stock
fell 55 percent to $2.20 a share. CellCyte traded at a high of $7.02
per share just days before.

If you purchased CellCyte shares during the period from April 6,
2007 through January 9, 2008, inclusive, you may, no later than March
14, 2008, move the court to be appointed as Lead Plaintiff. There are
certain legal requirements to serve as Lead Plaintiff. Any member of
the proposed class may move the court to serve as Lead Plaintiff
through counsel of their choice or may choose to remain an absent
class member. Your ability to share in any recovery is not, however,
affected by the decision whether or not to serve as Lead Plaintiff.

Cohen, Milstein, Hausfeld & Toll, P.L.L.C. has significant
experience in prosecuting investor class actions and actions involving
securities fraud. The firm has offices in Washington, D.C., New York,
Philadelphia, Chicago, San Francisco, and London, and is active in
major litigation pending in federal and state courts throughout the
nation.

The firm's reputation for excellence has repeatedly been
recognized by courts which have appointed the firm to lead positions
in complex multi-district or consolidated litigation. Cohen, Milstein,
Hausfeld & Toll, P.L.L.C. has taken a lead role in numerous important
cases on behalf of defrauded investors, and has been responsible for a
number of outstanding recoveries which, in the aggregate, total in the
billions of dollars.

If you have any questions about this notice or the action, or with
regard to your rights, please contact either of the following:

-0-
*T
Steven J. Toll, Esq.
Dana Frusco
Cohen, Milstein, Hausfeld & Toll, P.L.L.C.
1100 New York Avenue, N.W.
West Tower, Suite 500
Washington, D.C. 20005
Telephone: (888) 240-0775 or (202) 408-4600
E-mail: stoll@cmht.com or dfrusco@cmht.com
*T

Cohen, Milstein, Hausfeld & Toll, P.L.L.C.
Steven J. Toll, Esq.
888-240-0775
202-408-4600
stoll@cmht.com
or
Dana Frusco
888-240-0775
202-408-4600
dfrusco@cmht.com

Copyright Business Wire 2008